New drug hope for advanced skin cancer patients
NCT ID NCT05070403
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether the drug afatinib can shrink tumors in people with advanced cutaneous squamous cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. About 25 adults with adequate organ function will receive afatinib, and researchers will measure how many respond and how long they live without the cancer growing. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Glowing cancer cells: a new way to see tumors during surgery?
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- Immunotherapy before surgery may cut skin cancer recurrence
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients